Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials - PubMed (original) (raw)

Meta-Analysis

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

Jonathan Afilalo et al. Heart. 2007 Aug.

Abstract

Background: Intensive statin therapy reduces major adverse cardiovascular events (MACE), but the effect on mortality is unclear.

Objective: To determine whether intensive statin therapy reduces all-cause mortality compared with moderate statin therapy in patients with recent acute coronary syndromes (ACS) and stable coronary heart disease (CHD).

Methods: Medline, Embase, the Cochrane Database, the internet, and conference proceedings from 1966 to 2006 were searched to identify relevant trials. Selection criteria were randomised allocation to intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day, or rosuvastatin 20-40 mg/day) versus moderate statin therapy, recent ACS or stable CHD at the time of randomisation, and > or =6 months of follow-up.

Results: Six trials, encompassing 110 271 patient-years, were pooled. In patients with recent ACS, intensive statin therapy reduced all-cause mortality from 4.6% to 3.5% over 2.0 years (OR = 0.75, 95% CI 0.61 to 0.93). In patients with stable CHD, intensive statin therapy had no effect on all-cause mortality over 4.7 years (OR = 0.99, 95% CI 0.89 to 1.11). Overall, intensive statin therapy was associated with a reduction in MACE (OR = 0.84, 95% CI 0.77 to 0.91) and admissions to hospital for heart failure (OR = 0.72, 95% CI 0.62 to 0.83). Intensive statin therapy was also associated with an increase in hepatic transaminases >3 times normal (OR = 3.73, 95% CI 2.11 to 6.58) and a trend towards increased creatine kinase >10 times normal and/or rhabdomyolysis (OR = 1.96, 95% CI 0.50 to 7.63).

Conclusions: Compared with moderate statin therapy, intensive statin therapy reduces all-cause mortality in patients with recent ACS but not in patients with stable CHD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors of this meta‐analysis have no personal or financial conflicts of interest to report. All authors had full access to all the data and had final responsibility for the decision to submit for publication.

Figures

Similar articles

Cited by

References

    1. Baigent C, Keech A, Kearney P M.et al Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 20053661267–1278. - PubMed
    1. O'Keefe J H, Jr, Cordain L, Harris W H.et al Optimal low‐density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004432142–2146. - PubMed
    1. Ray K K, Cannon C P. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 200415637–643. - PubMed
    1. Takemoto M, Liao J K. Pleiotropic effects of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001211712–1719. - PubMed
    1. Kinlay S, Schwartz G G, Olsson A G.et al High‐dose atorvastatin enhances theline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 20031081560–1566. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources